image credit- shutterstock
Mumbai-based Shashvi Remedies, a pioneer in healthcare innovation, has received a grant of Rs ten lakh for international patents from the Maharashtra State Innovation Society (MSINS) under the Government of Maharashtra's Skill Development and Entrepreneurship Department (SDED).
This acknowledgement is the demonstration of Shashvi Remedies’ persistent endeavour to identify pharma solutions for critical cancer disease that contributes to making a difference.
With breast cancer affecting over 670,000 women worldwide each year and one woman diagnosed every four minutes in India, the need for breakthrough treatments has never been more urgent. Shashvi Remedies’ patented innovation offers new hope by targeting and eliminating cancerous cells while preserving healthy tissue, representing a major step forward in patient-centered treatment options.
As the global pharmaceutical industry braces for the upcoming patent cliff of 2030, which will see the expiration of several major drug patents, Shashvi’s patented innovation is poised to capture attention.
Industry analysts predict that pharmaceutical giants will be investing heavily in patented oncology solutions, with over $500 billion in reserves for acquisitions and pipeline growth. Shashvi’s patented breast cancer treatment is a highly valuable asset, with both Indian and global pharmaceutical companies recognizing its potential.
A recent example of this trend is the acquisition of a US-based R&D firm by a leading Indian pharmaceutical company, securing a derma-oncology product for approximately $355 million—demonstrating the industry’s keen interest in breakthrough, early-stage oncology solutions.
